Therapy for the NRAS melanoma subtype
At a glance
- Project leader : Prof. Dr. Rainer Riedl
- Project status : ongoing
- Funding partner : Innosuisse (Innovationsprojekt / Projekt Nr. 103.243.1 IP-LS)
- Contact person : Rainer Riedl
Description
Melanoma is the fifth most common cancer in Switzerland and the most lethal skin cancer. NRAS (neuroblastoma ras viral oncogene homolog)-mutated melanoma is the most aggressive subtype, with no effective therapy after immunotherapy failure. The goal of this project is to develop the first effective targeted therapy combination against this often fatal disease.